Samsung Biologics / PolyPeptide: What the Tender Close on 12 October Means for Peptide API Supply Chains

Key takeaways

• The main acceptance period for Samsung Biologics' all-cash tender offer for PolyPeptide Group closes at 4 p.m. Swiss time on 12 October 2026, with completion of the acquisition targeted towards the end of 2026.
• The offer values PolyPeptide at approximately CHF 1.46 billion (roughly USD 1.8 billion), a 40% premium to the unaffected share price, and has unanimous board support backed by an independent fairness opinion.
• PolyPeptide reported 41.6% revenue growth in H1 2026, driven by a 72.7% surge in metabolic therapeutics, which now represent approximately 68% of total revenue — underscoring why Samsung sought the asset.
• PolyPeptide's six cGMP development and manufacturing facilities span Europe (Belgium, France, Sweden), the US (California), and India; European sites are the primary source of peptide APIs supplied into UK and continental pharma programmes.
• Successful completion would create the world's largest integrated multi-modality CDMO with dedicated peptide API capacity, altering competitive dynamics for contract manufacturing of GLP-1 and other therapeutic peptides.

The deal at a glance

Samsung Biologics, the South Korean contract development and manufacturing organisation, announced a pre-offer intention to acquire PolyPeptide Group AG on 20 July 2026. The formal tender offer prospectus was published on 31 August 2026 through Samsung Biologics' wholly owned Swiss subsidiary, Samsung Peptide AG.

According to Samsung Biologics' prospectus documentation, the main offer period commenced on 15 September 2026 and is expected to close on 12 October 2026 at 4 p.m. Swiss time. The offer is denominated at CHF 44.31 net in cash per registered share, implying an aggregate equity value of approximately CHF 1.46 billion.

The offer carries a 40% premium to PolyPeptide's unaffected closing share price on 10 April 2026 — the last trading session before media speculation surfaced — and an 11.6% premium to the volume-weighted average price across the 60 preceding trading days. The offer requires a minimum acceptance threshold of 66⅔% on a fully diluted share count basis (excluding treasury shares), plus applicable regulatory approvals.

Shareholder commitment is substantial. Draupnir Holding B.V., PolyPeptide's largest individual shareholder at approximately 55.65% of outstanding shares, has committed to tender its entire position. The PolyPeptide board unanimously recommended acceptance, supported by an independent fairness opinion from IFBC AG. With Draupnir alone exceeding the majority acceptance threshold, minority participation is commercially rational but not mathematically decisive to clearing the 66⅔% condition.

Following settlement, Samsung Peptide intends to pursue a squeeze-out of any remaining minority shareholders and delist PolyPeptide's shares from the SIX Swiss Exchange.

The transaction is described as the largest merger and acquisition in the history of South Korea's pharmaceutical and biotechnology industry.

Why Samsung pursued this asset

Samsung Biologics' existing business is centred on biologics, antibody drug conjugates, and advanced therapies. Peptide synthesis — particularly the solid-phase peptide synthesis (SPPS) chemistry used to produce GLP-1 analogues and other complex therapeutic peptides at scale — is a materially different manufacturing discipline requiring dedicated equipment, specialist chemistry know-how, and cGMP-qualified infrastructure that cannot be built greenfield on a short timeline.

The transaction will enable Samsung Biologics to expand its capabilities to include peptide therapeutics, particularly for treatments targeting obesity and type-2 diabetes. It combines Samsung's global manufacturing scale with PolyPeptide's specialised expertise, creating what both parties describe as a differentiated, multimodality CDMO platform.

The timing is instructive. Announced peptide CDMO investments crossed USD 2.4 billion year-to-date in 2026, driven by GLP-1 demand and a broadening pipeline of therapeutic peptides, yet lead times for large-scale SPPS capacity additions remain 18–36 months, creating a near-term supply bottleneck even as capital commitments accumulate. Acquiring PolyPeptide provides Samsung with operational capacity immediately, rather than waiting for greenfield builds.

PolyPeptide's financial position at the time of sale

The financial backdrop to the offer is markedly positive for PolyPeptide, which may explain why Samsung moved decisively on price. PolyPeptide reported revenue of EUR 236.6 million in H1 2026, up 41.6% year-on-year (43.7% at constant currency), driven primarily by growth in metabolic therapeutics.

Revenue from metabolic therapeutics grew 72.7% versus H1 2025, reaching 68.4% of total revenue — compared with approximately 27% of total revenue in H1 2021. That structural shift reflects the company's deliberate positioning in GLP-1 and related metabolic peptide manufacturing.

Profitability recovered sharply. EBITDA reached EUR 49.1 million in H1 2026, lifting the margin to 20.7% from just 2.7% in H1 2025, driven by higher volumes, improved operational leverage, and high utilisation at the large-scale SPPS facility in Braine-l'Alleud, Belgium. Net profit swung to EUR 9.1 million from a loss of EUR 26.5 million in H1 2025.

Development revenue increased 52.3% year-on-year, supported by strong demand from late-stage clinical programmes — a leading indicator of future commercial manufacturing volumes. Management subsequently raised full-year 2026 guidance to 25–30% revenue growth and a high-teens EBITDA margin, confirming its medium-term outlook to double 2023 revenues by 2028.

The manufacturing network: what changes — and what does not

PolyPeptide's manufacturing network spans six cGMP facilities. The sites are: Braine-l'Alleud (Belgium), Strasbourg (France), Malmö (Sweden), Torrance and San Diego (California, USA), and Ambernath (India). There is no UK-domiciled site, but the three European facilities in Belgium, France, and Sweden are the principal sources of cGMP peptide APIs supplied to UK pharmaceutical and research organisations under existing contracts.

Key capacity investments remain in progress. The new SPPS capacity at Strasbourg had become operational and was expected to ramp up production throughout 2026. In Malmö, the doubling of SPPS capacity — a EUR 100 million investment — is underway, with approximately 100 permanent positions to be created. The Malmö facility has received GMP certification from the Swedish MPA and has also been inspected and approved by the US FDA and the Japanese PMDA.

The Braine-l'Alleud site is the company's largest commercial production asset. The large-scale SPPS capacity at Braine was operating at target utilisation in H1 2026, with optimisation measures having raised potential annual revenue from the asset from approximately EUR 100 million to EUR 125 million.

Samsung has stated publicly that it does not intend to disrupt ongoing customer relationships or manufacturing programmes during the transition. Post-settlement, Samsung Peptide intends to integrate PolyPeptide's capabilities with Samsung Biologics' existing CDMO operations, though an integration timeline has not been disclosed.

Implications for research-procurement teams

For UK and European research organisations currently sourcing peptide APIs through PolyPeptide — whether for clinical development programmes, reference standards, or preclinical research batches — the near-term practical impact is expected to be limited. Existing supply agreements are contractual obligations that transfer with the business, and PolyPeptide's management and site-level operations are not expected to change at close.

The medium-term considerations are more substantive. Once integrated into a USD-scale CDMO with Samsung Biologics' balance sheet behind it, PolyPeptide's capacity expansion plans — the Malmö doubling, the Strasbourg ramp — have considerably stronger financial backing. That should, in principle, increase the probability that new capacity comes online to schedule, easing the 18–36 month SPPS supply bottleneck that has characterised the GLP-1 manufacturing landscape since 2024.

At the same time, strategic prioritisation within a larger organisation can shift. Research organisations that source small-volume, non-commercial grade material may find that a Samsung-owned PolyPeptide progressively focuses its commercial attention on large-volume, long-term clinical and commercial supply contracts — the high-margin segment its H1 2026 financials demonstrate is growing fastest. Procurement teams sourcing small-batch or development quantities would be prudent to confirm continuity of service terms with their account managers before year-end.

The broader consolidation context is also relevant. Samsung Biologics chose to buy scaled peptide manufacturing outright rather than build it, underscoring how tight obesity-drug supply chains have become. The Bachem re-rating thesis, articulated by analysts at the time of the deal announcement, reflects an industry-wide read-through: independent specialist peptide CDMOs are scarce assets, and their scarcity premium is rising as GLP-1 commercial volumes continue to grow.

What to watch

• 12 October 2026: Main offer acceptance period closes at 4 p.m. Swiss time. Samsung Biologics is expected to publish a results statement shortly thereafter confirming whether the 66⅔% minimum acceptance threshold has been met.
• Regulatory clearances: The offer is subject to applicable regulatory approvals across relevant jurisdictions. No specific regulatory objections have been reported publicly.
• Squeeze-out and delisting: If the threshold is met, Samsung Peptide intends to pursue a squeeze-out of remaining minority shareholders and apply to delist PolyPeptide from the SIX Swiss Exchange, ending its independent listed history.
• Integration announcements: Any public statements from Samsung Biologics regarding post-close management structure, customer programme continuity, or facility investment timelines will be material for research and development partners of PolyPeptide.